The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Open accessAbstract
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor prognosis. The incidence of HCC and HCC-related deaths have increased over the last several decades. However, the treatment options for advanced HCC are very limited. Sorafenib remains the only drug approved for systemic treatment for advanced HCC. However, prior to sorafenib era conventional cytotoxic chemotherapies have been studied in advanced HCC. In this review, clinical studies of systemic chemotherapy for advanced HCC will be summarized and discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Stimpfel, M., & Virant-Klun, I. (2016) · Journal of Cancer Stem Cell Research · doi:10.14343/jcscr.2016.4e1003 · Cited by 2,540
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Lee, J. T., Chang, F., Bertrand, F. E., Navolanic, P. M., Terrian, D. M., Franklin, R. A., D’Assoro, A. B., et al. (2006) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.01.004 · Cited by 664
Yeo, W., Mok, T. S., Zee, B., Leung, T. W. T., Lai, P. B. S., Lau, W. Y., Koh, J., Mo, F. K. F., Yu, S. C. H., Chan, A. T., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji315 · Cited by 590
Siegel, A. B., Cohen, E. I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A., Mandeli, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9947 · Cited by 506
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
Abou-Alfa, G. K., Johnson, P., Knox, J. J., Capanu, M., Davidenko, I., Lacava, J., Leung, T., Gansukh, B., & Saltz, L. B. (2010) · JAMA · doi:10.1001/jama.2010.1672 · Cited by 448
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., Sheehan, S., Hale, K. E., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Lavie, Y., Cao, H.-T., Volner, A., Lucci, A., Han, T.-Y., Geffen, V., Giuliano, A. E., & Cabot, M. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.3.1682 · Cited by 284
Gish, R. G., Porta, C., Lazar, L., Ruff, P., Feld, R., Croitoru, A., Feun, L., Jeziorski, K., Leighton, J., Knox, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.4046 · Cited by 279
Leung, T. W. T., Patt, Y. Z., Lau, W. Y., Ho, S. K. W., Yu, S. C. H., Chan, A. T. �., Mok, T. S. K., Yeo, W., Liew, C.-T., Leung, N. W. Y., et al. (1999) · PubMed · Cited by 278
Prognosis of untreated hepatocellular carcinoma
Giannini, E. G., Farinati, F., Ciccarese, F., Pecorelli, A., Rapaccini, G. L., Di Marco, M., Benvegnù, L., Caturelli, E., Zoli, M., Borzio, F., et al. (2015) · Hepatology · doi:10.1002/hep.27443 · Cited by 250
Floros, T., & Tarhini, A. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.015 · Cited by 229
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma
Pang, R., & Poon, R. T. P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.01.008 · Cited by 210
Chow, P. K. H., Tai, B.-C., Tan, C.-K., Machin, D., Win, K. M., Johnson, P. J., & Soo, K.-C. (2002) · Hepatology · doi:10.1053/jhep.2002.36824 · Cited by 209
Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial
(1998) · The Lancet · doi:10.1016/s0140-6736(98)01259-8 · Cited by 202
Patt, Y. Z., Hassan, M. M., Lozano, R. D., Brown, T. D., Vauthey, J. N., Curley, S. A., & Ellis, L. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.103 · Cited by 200
Louafi, S., Boige, V., Ducreux, M., Bonyhay, L., Mansourbakht, T., de Baere, T., Asnacios, A., Hannoun, L., Poynard, T., & Taïeb, J. (2007) · Cancer · doi:10.1002/cncr.22532 · Cited by 195
Castells, A., Bruix, J., Brú, C., Ayuso, C., Roca, M., Boix, L., Vilana, R., & Rodés, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90402-6 · Cited by 187
Maria, N. D., Manno, M., & Villa, E. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00096-5 · Cited by 179
The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis
Berasain, C., & Avila, M. A. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-013-0907-x · Cited by 174
Twelves, C., Glynne‐Jones, R., Cassidy, J., Schüller, J., Goggin, T. K., Roos, B., Banken, L., Utoh, M., Weidekamm, E., & Reigner, B. G. (1999) · PubMed · Cited by 155
Kubicka, S., Rudolph, K. L., Tietze, M. K., et al. (2002) · PubMed · Cited by 147
Role of estrogen in hepatocellular carcinoma: is inflammation the key?
Shi, L., Feng, Y.-L., Lin, H. M., Ma, R., & Cai, X. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-93 · Cited by 144
Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O., Brendel, E., Schwartz, B. E., Ludwig, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl017 · Cited by 142
Asnacios, A., Fartoux, L., Romano, O., Tesmoingt, C., Louafi, S., Mansoubakht, T., Artru, P., Poynard, T., Rosmorduc, O., Hebbar, M., et al. (2008) · Cancer · doi:10.1002/cncr.23489 · Cited by 135
Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma
Barbare, J., Bouché, O., Bonnetain, F., Raoul, J., Rougier, P. R., Abergel, A., Boige, V., Denis, B., Blanchi, A., Pariente, A. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.470 · Cited by 134
Hsu, C., Yang, T.-S., Hsu, C., Toh, H. C., Epstein, R. J., Hsiao, L.-T., Chen, P.-J., Lin, Z.-Z., Chao, T.-Y., & Cheng, A.-L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605580 · Cited by 131
Becker, G., Allgaier, H., Olschewski, M., Zähringer, A., & Blum, H. E. (2006) · Hepatology · doi:10.1002/hep.21468 · Cited by 115
Jiang, W., Lu, Z., He, Y., & Diasio, R. B. (1997) · PubMed · Cited by 113
Leung, T. W. T., Tang, A. M. Y., Zee, B. C.-Y., Yu, S. C. H., Lai, P. B. S., Lau, W. Y., & Johnson, P. J. (2002) · Cancer · doi:10.1002/cncr.10236 · Cited by 112
Abou‐Alfa, G. K., Niedzwieski, D., Knox, J. J., Kaubisch, A., Posey, J. A., Tan, B. R., Kavan, P., Goel, R., MURRAY, J. J., Bekaii‐Saab, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.192 · Cited by 100
Sun, W., Sohal, D. P. S., Haller, D. G., Mykulowycz, K., Rosen, M. A., Soulen, M. C., Caparro, M., Teitelbaum, U. R., Giantonio, B. J., O'Dwyer, P. J., et al. (2011) · Cancer · doi:10.1002/cncr.25889 · Cited by 99
Kato, A., Miyazaki, M., Ambiru, S., Yoshitomi, H., Ito, H., Nakagawa, K., Shimizu, H., Yokosuka, O., & Nakajima, N. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1129 · Cited by 97
Systemic therapy of hepatocellular carcinoma: Are we making progress?
Roxburgh, P., & Evans, T. R. J. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0113-z · Cited by 95
Park, S. H., Lee, Y., Han, S. H., Kwon, S. Y., Kwon, O. S., Kim, S. S., Kim, J. H., Park, Y. H., Lee, J. N., Bang, S., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-3 · Cited by 88
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
Lee, J., Park, J. O., Kim, W. S., Park, S. H., Park, K. W., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., Yoo, B. C., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0837-7 · Cited by 83
A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma
O'Reilly, E. M., Stuart, K. E., Sanz-Altamira, P. M., Schwartz, G. K., Steger, C., Raeburn, L., Kemeny, N. E., Kelsen, D. P., & Saltz, L. B. (2001) · Cancer · Cited by 83
Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
Brandi, G., Rosa, F. D., Agostini, V., Girolamo, S. D., Andreoné, P., Bolondi, L., Serra, C., Sama, C., Golfieri, R., Gramenzi, A., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0093 · Cited by 72
Boige, V., Taïeb, J., Hebbar, M., Malka, D., de Baère, T., Hannoun, L., Magherini, E., Mignard, D., Poynard, T., & Ducreux, M. P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.034 · Cited by 64
Barbare, J., Bouché, O., Bonnetain, F., Dahan, L., Lombard‐Bohas, C., Faroux, R., Raoul, J., Cattan, S., Lemoine, A., Blanc, J., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.018 · Cited by 64
Lombardi, G., Zustovich, F., Farinati, F., Cillo, U., Vitale, A., Zanus, G., Donach, M. E., Farina, M., Zovato, S., & Pastorelli, D. (2010) · Cancer · doi:10.1002/cncr.25578 · Cited by 63
Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas
Bläker, M., Schmitz, M., Gocht, A., Burghardt, S., Schulz, M., Bröring, D. C., Pace, A., Greten, H., & de Weerth, A. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.03.018 · Cited by 63
on behalf of the Asia-Pacific Hepatocellular Carcinoma Trials Group, Chow, P. K. H., Machin, D., Chen, Y., Zhang, X., Win, K. M., Hoang, H.-H., Nguyen, B.-D., Jin, M.-Y., Lobo, R., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.333 · Cited by 42
Kaseb, A. O., Shindoh, J., Patt, Y. Z., Roses, R. E., Zimmitti, G., Lozano, R. D., Hassan, M. M., Hassabo, H. M., Curley, S. A., Aloia, T. A., et al. (2013) · Cancer · doi:10.1002/cncr.28209 · Cited by 32
Cited by
Dimitroulis, D., Damaskos, C., Valsami, S., Davakis, S., Garmpis, N., Spartalis, E., Athanasiou, A., Moris, D., Sakellariou, S., Kykalos, S., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i29.5282 · Cited by 330
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Zhao, Y., Zhang, Y.-N., Wang, K.-T., & Chen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188391 · Cited by 278
Yang, C., Huang, X., Li, Y., Chen, J., Lv, Y., & Dai, S. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa164 · Cited by 269
Immunotherapy for hepatocellular carcinoma
Zongyi, Y., & Xiaowu, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.12.002 · Cited by 265
Gu, L., Zhu, Y., Lin, X., Tan, X., Lu, B., & Li, Y. (2020) · Oncogene · doi:10.1038/s41388-020-1156-0 · Cited by 156
Metadata
- Authors
- Kim, D. W., Talati, C., & Kim, R.
- Venue
- Journal of Gastrointestinal Oncology
- Publisher
- AME Publishing Company
- Published
- 2017-04
- Volume
- 8
- Issue
- 2
- Pages
- 256-265
- ISSN
- 2078-6891 (ISSN-L)
- 2219-679X
- OpenAlex
- W2530417471
- Cited by
- 333
- References
- 49
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.